Display options
Cite
Vincent J, Harris SI, Foulds G, et al. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br J Clin Pharmacol. 2000;50(5):455-63doi: 10.1046/j.1365-2125.2000.00283.x.
Vincent, J., Harris, S. I., Foulds, G., Dogolo, L. C., Willavize, S., & Friedman, H. L. (2000). Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. British journal of clinical pharmacology, 50(5), 455-63. https://doi.org/10.1046/j.1365-2125.2000.00283.x
Vincent, J, et al. "Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine." British journal of clinical pharmacology vol. 50,5 (2000): 455-63. doi: https://doi.org/10.1046/j.1365-2125.2000.00283.x
Vincent J, Harris SI, Foulds G, Dogolo LC, Willavize S, Friedman HL. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br J Clin Pharmacol. 2000 Nov;50(5):455-63. doi: 10.1046/j.1365-2125.2000.00283.x. PMID: 11069440; PMCID: PMC2014412.
Copy Download .nbib Format: NLM
Share it on

Br J Clin Pharmacol. 2000 Nov;50(5):455-63. doi: 10.1046/j.1365-2125.2000.00283.x.

Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine.

British journal of clinical pharmacology

J Vincent, S I Harris, G Foulds, L C Dogolo, S Willavize, H L Friedman

Affiliations

  1. Clinical Pharmacology Division, Pfizer Central Research, Groton, CT 06340, USA.

PMID: 11069440 PMCID: PMC2014412 DOI: 10.1046/j.1365-2125.2000.00283.x

Abstract

AIMS: To determine whether repeated once daily administration of grapefruit juice altered the pharmacokinetics or pharmacodynamics of the calcium antagonist amlodipine.

METHOD: S The effects of grapefruit juice on the pharmacokinetics and pharmacodynamics of oral and intravenous amlodipine were assessed in 20 healthy men in a placebo-controlled, open, randomized, four-way crossover study using single doses of amlodipine 10 mg. For 9 days beginning with the day of administration of amlodipine, grapefruit juice (or water control) was given once daily, and blood samples, blood pressure and heart rate measures were obtained. Plasma concentrations of amlodipine and its enantiomers were determined in separate assays by GC-ECD.

RESULTS: Oral amlodipine had high systemic availability (grapefruit juice: 88%; water: 81%). Pharmacokinetic parameters of racemic amlodipine (AUC, Cmax, tmax, and kel) were not markedly changed with grapefruit juice coadministration. Total plasma clearance and volume of distribution, calculated after intravenous amlodipine, were essentially unchanged by grapefruit juice (CL 6.65 ml min-1 kg-1, juice vs 6.93 ml min-1 kg-1, water; Vdss 22.7 l kg-1, juice vs 21.0 l kg-1, water). Grapefruit juice coadministration did not greatly alter the stereoselectivity in amlodipine oral or intravenous kinetics. The sum of S(-) and R(+) enantiomer concentrations correlated well with total racemic amlodipine concentration (r2 = 0. 957; P = 0.0001). Coadministration of grapefruit juice with either route of amlodipine administration did not significantly alter blood pressure changes vs control.

CONCLUSIONS: Grapefruit juice has no appreciable effect on amlodipine pharmacodynamics or pharmacokinetics, including its stereoselective kinetics. Bioavailability enhancement by grapefruit juice, noted with other dihydropyridine calcium antagonists, does not occur with amlodipine. Once daily grapefruit juice administration with usual oral doses of amlodipine is unlikely to alter the profile of response in clinical practice.

References

  1. Br J Clin Pharmacol. 1998 Aug;46(2):101-10 - PubMed
  2. Pharm Res. 1998 Jul;15(7):1001-6 - PubMed
  3. Clin Pharmacol Ther. 1999 Mar;65(3):237-44 - PubMed
  4. Clin Pharmacol Ther. 1999 Oct;66(4):408-14 - PubMed
  5. Clin Pharmacol Ther. 1999 Nov;66(5):448-53 - PubMed
  6. Clin Pharmacol Ther. 2000 Mar;67(3):201-14 - PubMed
  7. Clin Pharmacol Ther. 1981 Sep;30(3):311-6 - PubMed
  8. Circulation. 1982 May;65(5):998-1003 - PubMed
  9. Br J Clin Pharmacol. 1986 Jul;22(1):21-5 - PubMed
  10. J Pharm Sci. 1987 Apr;76(4):310-3 - PubMed
  11. J Chromatogr. 1987 Sep 4;420(1):178-83 - PubMed
  12. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7735-8 - PubMed
  13. J Cardiovasc Pharmacol. 1988 Jul;12(1):1-5 - PubMed
  14. J Cardiovasc Pharmacol. 1988;12 Suppl 7:S55-9 - PubMed
  15. Arzneimittelforschung. 1989 Feb;39(2):201-9 - PubMed
  16. Am Heart J. 1989 Nov;118(5 Pt 2):1100-3 - PubMed
  17. J Med Chem. 1991 Jun;34(6):1838-44 - PubMed
  18. Clin Pharmacol Ther. 1991 Oct;50(4):394-403 - PubMed
  19. Clin Pharmacokinet. 1992 Jan;22(1):22-31 - PubMed
  20. Xenobiotica. 1994 Mar;24(3):243-50 - PubMed
  21. J Chromatogr A. 1995 Mar 3;694(1):181-93 - PubMed
  22. Mol Carcinog. 1995 Jul;13(3):129-34 - PubMed
  23. Br J Clin Pharmacol. 1995 Aug;40(2):135-40 - PubMed
  24. Eur J Clin Pharmacol. 1995;49(1-2):61-7 - PubMed
  25. Eur J Clin Pharmacol. 1996;51(2):189-93 - PubMed
  26. Clin Pharmacokinet. 1997 Aug;33(2):103-21 - PubMed

Substances

MeSH terms

Publication Types